Literature DB >> 20840378

Economic burden of Parkinson's disease in Singapore.

Y J Zhao1, L C S Tan, S C Li, W L Au, S H Seah, P N Lau, N Luo, H L Wee.   

Abstract

BACKGROUND: This study was carried out to evaluate the economic burden of Parkinson's disease (PD) and factors independently associated with individual components of total cost in Singapore.
METHODS: A consecutive sample of 195 patients with PD (mean age: 68.2, men: 51.8%) attending a tertiary neuroscience clinic were identified and interviewed using standardized questionnaires including a financial burden questionnaire, two Health Related Quality of Life (HRQoL) questionnaires and the Beck Depression Inventory questionnaire.
RESULTS: Annual total cost of PD from a societal perspective was SGD11345 (USD10129) per patient, with direct cost accounted for 38.5% and indirect cost 61.5%. The main cost components for direct medical cost, direct non-medical cost, and indirect cost was pharmacotherapy (50.4%), home care (76.1%), and productivity loss (97.9%), respectively. In multiple linear regression analysis, higher education, younger age and longer duration of PD were associated with higher total cost.
CONCLUSIONS: Parkinson's disease exerts a considerable burden on patients, health care system and society in Singapore. As productivity loss accounts for a large share of the economic burden imposed by PD, treatments and health care programmes with potential for returning patients to higher productivity are urgently needed.
© 2010 The Author(s). European Journal of Neurology © 2010 EFNS.

Entities:  

Mesh:

Year:  2010        PMID: 20840378     DOI: 10.1111/j.1468-1331.2010.03210.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  8 in total

Review 1.  Integrating Patient Concerns into Parkinson's Disease Management.

Authors:  Shen-Yang Lim; Ai Huey Tan; Susan H Fox; Andrew H Evans; Soon Chai Low
Journal:  Curr Neurol Neurosci Rep       Date:  2017-01       Impact factor: 5.081

Review 2.  Early versus delayed initiation of pharmacotherapy in Parkinson's disease.

Authors:  Matthias Löhle; Carl-Johan Ramberg; Heinz Reichmann; Anthony H V Schapira
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

3.  Economic burden of irritable bowel syndrome in China.

Authors:  Fang Zhang; Wei Xiang; Chun-Yan Li; Shu-Chuen Li
Journal:  World J Gastroenterol       Date:  2016-12-21       Impact factor: 5.742

Review 4.  Systematic Review and Critical Analysis of Cost Studies Associated with Parkinson's Disease.

Authors:  Tânia M Bovolenta; Sônia Maria Cesar de Azevedo Silva; Roberta Arb Saba; Vanderci Borges; Henrique Ballalai Ferraz; Andre C Felicio
Journal:  Parkinsons Dis       Date:  2017-03-05

5.  Resource Utilization of Patients with Parkinson's Disease in the Late Stages of the Disease in Germany: Data from the CLaSP Study.

Authors:  Christopher Kruse; Sabrina Kretschmer; Anna Lipinski; Malte Verheyen; David Mengel; Monika Balzer-Geldsetzer; Stefan Lorenzl; Carmen Richinger; Christian Schmotz; Lars Tönges; Dirk Woitalla; Stephan Klebe; Anette Schrag; Richard Dodel
Journal:  Pharmacoeconomics       Date:  2021-03-19       Impact factor: 4.981

6.  Measuring the lifespace of people with Parkinson's disease using smartphones: proof of principle.

Authors:  Jacki Liddle; David Ireland; Simon J McBride; Sandra G Brauer; Leanne M Hall; Hang Ding; Mohan Karunanithi; Paul W Hodges; Deborah Theodoros; Peter A Silburn; Helen J Chenery
Journal:  JMIR Mhealth Uhealth       Date:  2014-03-12       Impact factor: 4.773

7.  Average annual cost of Parkinson's disease in São Paulo, Brazil, with a focus on disease-related motor symptoms.

Authors:  Tânia M Bovolenta; Sônia Maria Cesar de Azevedo Silva; Roberta Arb Saba; Vanderci Borges; Henrique Ballalai Ferraz; Andre C Felicio
Journal:  Clin Interv Aging       Date:  2017-12-14       Impact factor: 4.458

8.  Direct Medical Costs of Parkinson's Disease in Southern China: A Cross-Sectional Study Based on Health Insurance Claims Data in Guangzhou City.

Authors:  Hui Zhang; Wenjing Zhou; Donglan Zhang
Journal:  Int J Environ Res Public Health       Date:  2022-03-09       Impact factor: 3.390

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.